EGFR (HER1) highlights as one of the most relevant tumor associated antigen in epithelial malignant cells. Monoclonal antibodies and tyrosine kinase inhibitors against EGFR remain as the most advanced approaches in clinical trials. More recently, an active immunotherapy using the HER1 extracellular domain (ECD) adjuvated in very small size proteoliposomes (VSSP) and emulsified in Montanide ISA-51 demonstrated its strength to inhibit tumor cell line proliferation by arresting cells in G(0)/G(1) stage and induction of apoptosis. In this study, we present a simpler HER1-ECD-based formulation, which is lacking the oily component Montanide ISA-51. Generated antibodies following non-emulsive formulation immunization recognized membrane EGFR; avoid EGF and TGFalpha coupling to EGFR leading to a marked abrogation of EGFR phosphorylation levels. Non-emulsive formulation also arrests cell cycle in G(0)/G(1) stage, demonstrating it preserves previous formulation quality in a newer and simpler formulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4161/hv.5.3.7129 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
Front Oncol
October 2024
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Article Synopsis
- Acute myeloid leukemia (AML) has a poor prognosis mainly due to the relapse driven by therapy-resistant leukemia progenitor/stem cells (LPCs), leading to the development of peptide-based immunotherapy targeting these cells to improve patient outcomes.
- A therapeutic vaccine called AML-VAC-XS15 was created, consisting of specific peptides from common AML mutations, and is being tested in a phase I clinical trial for its effectiveness and safety in AML patients in remission.
- The study is ethically approved and aims to evaluate the vaccine's ability to generate immune responses and assess its preliminary clinical efficacy while ensuring patient safety through monitoring over two years.
Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine.
Appl Microbiol Biotechnol
October 2024
Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, 106, Taiwan.
Article Synopsis
- A study found that a specific peptide from the SARS-CoV-2 spike protein (S(1144-1156)) can broadly neutralize multiple COVID-19 variants, including Delta and Omicron.
- Mice vaccinated with this peptide produced high levels of specific antibodies and immune responses, indicating its potential as a vaccine candidate.
- Enhanced neutralizing antibody responses were also seen with slightly modified peptides (S(1143-1157) and S(1142-1158)), suggesting improvements in vaccine design for COVID-19.
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.
Front Oncol
August 2024
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia among adults in Western countries. Despite the introduction of targeted therapies, including first-line Bruton's tyrosine kinase inhibitor (BTKi) treatment, CLL remains largely incurable. Frequent disease relapses occur due to remaining treatment-resistant CLL cells, calling for novel therapies to eliminate minimal residual disease (MRD).
View Article and Find Full Text PDFBackground: 48/45, a gametocyte surface protein, is a promising candidate for malaria transmission-blocking (TB) vaccine. Due to its relevance for a multispecies vaccine, we explored the cross-reactivity and TB activity of a recombinant 48/45 protein (r48/45) with sera from -exposed African donors.
Methods: r48/45 was produced in Chinese hamster ovary cell lines and tested by ELISA for its cross-reactivity with sera from Burkina Faso, Tanzania, Mali, and Nigeria - In addition, BALB/c mice were immunized with the r48/45 protein formulated in Montanide ISA-51 and inoculated with a crude extract of NF-54 gametocytes to evaluate the parasite-boosting effect on r48/45 antibody titers.
A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax.
NPJ Vaccines
December 2023
Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Plasmodium vivax (P. vivax) is the major malaria parasite outside of Africa and no vaccine is available against it. A vaccine that interrupts parasite transmission (transmission-blocking vaccine, TBV) is considered highly desirable to reduce the spread of P.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!